Louise E.J. Thomson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Louise E.J. Thomson has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Daniel S. Berman
Cedars-Sinai Medical Center, Los Angeles, CA (D.S.B.).
8 shared publications - Cathleen Noel Bairey Merz
Barbra Streisand Women’s Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
5 shared publications John D. Friedman
Department of Imaging and Medicine and the Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
5 shared publicationsSean W. Hayes
Department of Medicine, Division of Artificial Intelligence in Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States
5 shared publications- Carl J. Pepine
University of Florida
3 shared publications - Chrisandra Shufelt
Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL
3 shared publications
Latest Publications
- 7 June 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (4) , 409-415
Prognostic value of plaque burden assessed by coronary CT angiography in known coronary artery disease
- 7 June 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (4) , 409-415
Prognostic value of plaque burden assessed by coronary CT angiography in known coronary artery disease
- 7 June 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 50, 102270
82Rb positron emission tomography myocardial blood flow quantification: Influence of arterial input curve quality on diagnostic accuracy
- 7 June 2025
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 50, 102270
82Rb positron emission tomography myocardial blood flow quantification: Influence of arterial input curve quality on diagnostic accuracy
- 1 March 2022
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 16 (2) , 189-190
Detection of subclinical atherosclerosis from PET-CT in patients with breast cancer
- 1 March 2022
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 16 (2) , 189-190
Detection of subclinical atherosclerosis from PET-CT in patients with breast cancer
- 1 August 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 153, 36-42
Feasibility of Using an Ultrashort Lifestyle Questionnaire to Predict Future Mortality Risk among Patients with Suspected Heart Disease
- 1 August 2021
- Published by Elsevier in The American Journal of Cardiology
- Vol. 153, 36-42
Feasibility of Using an Ultrashort Lifestyle Questionnaire to Predict Future Mortality Risk among Patients with Suspected Heart Disease
- Open Access
- 1 June 2020
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 4 (3) , 229-237
Associations Among Self-reported Physical Activity, Coronary Artery Calcium Scores, and Mortality Risk in Older Adults
- 1 June 2020
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 4 (3) , 229-237
Open AccessAssociations Among Self-reported Physical Activity, Coronary Artery Calcium Scores, and Mortality Risk in Older Adults
- Open Access
- 20 December 2017
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 6 (12) , e255
Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial
Digital wearable devices provide a "real-world" assessment of physical activity and quantify intervention-related changes in clinical trials. However, the value of digital wearable device-recorded physical activity as a clinical trial outcome is unknown. Because late sodium channel inhibition (ranolazine) improves stress laboratory exercise duration among angina patients, we proposed that this benefit could be quantified and translated during daily life by measuring digital wearable device-determined step count in a clinical trial. We conducted a substudy in a randomized, double-blinded, placebo-controlled, crossover trial of participants with angina and coronary microvascular dysfunction (CMD) with no obstructive coronary artery disease to evaluate the value of digital wearable device monitoring. Ranolazine or placebo were administered (500-1000 mg twice a day) for 2 weeks with a subsequent 2-week washout followed by crossover to ranolazine or placebo (500-1000 mg twice a day) for an additional 2 weeks. The outcome of interest was within-subject difference in Fitbit Flex daily step count during week 2 of ranolazine versus placebo during each treatment period. Secondary outcomes included within-subject differences in angina, quality of life, myocardial perfusion reserve, and diastolic function. A total of 43 participants were enrolled in the substudy and 30 successfully completed the substudy for analysis. Overall, late sodium channel inhibition reduced within-subject daily step count versus placebo (mean 5757 [SD 3076] vs mean 6593 [SD 339], P=.01) but did not improve angina (Seattle Angina Questionnaire-7 [SAQ-7]) (P=.83). Among the subgroup with improved angina (SAQ-7), a direct correlation with increased step count (r=.42, P=.02) was observed. We report one of the first studies to use digital wearable device-determined step count as an outcome variable in a placebo-controlled crossover trial of late sodium channel inhibition in participants with CMD. Our substudy demonstrates that late sodium channel inhibition was associated with a decreased step count overall, although the subgroup with angina improvement had a step count increase. Our findings suggest digital wearable device technology may provide new insights in clinical trial research. Clinicaltrials.gov NCT01342029; https://clinicaltrials.gov/ct2/show/NCT01342029 (Archived by WebCite at http://www.webcitation.org/6uyd6B2PO).
- 20 December 2017
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 6 (12) , e255
Open AccessDaily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial
Digital wearable devices provide a "real-world" assessment of physical activity and quantify intervention-related changes in clinical trials. However, the value of digital wearable device-recorded physical activity as a clinical trial outcome is unknown. Because late sodium channel inhibition (ranolazine) improves stress laboratory exercise duration among angina patients, we proposed that this benefit could be quantified and translated during daily life by measuring digital wearable device-determined step count in a clinical trial. We conducted a substudy in a randomized, double-blinded, placebo-controlled, crossover trial of participants with angina and coronary microvascular dysfunction (CMD) with no obstructive coronary artery disease to evaluate the value of digital wearable device monitoring. Ranolazine or placebo were administered (500-1000 mg twice a day) for 2 weeks with a subsequent 2-week washout followed by crossover to ranolazine or placebo (500-1000 mg twice a day) for an additional 2 weeks. The outcome of interest was within-subject difference in Fitbit Flex daily step count during week 2 of ranolazine versus placebo during each treatment period. Secondary outcomes included within-subject differences in angina, quality of life, myocardial perfusion reserve, and diastolic function. A total of 43 participants were enrolled in the substudy and 30 successfully completed the substudy for analysis. Overall, late sodium channel inhibition reduced within-subject daily step count versus placebo (mean 5757 [SD 3076] vs mean 6593 [SD 339], P=.01) but did not improve angina (Seattle Angina Questionnaire-7 [SAQ-7]) (P=.83). Among the subgroup with improved angina (SAQ-7), a direct correlation with increased step count (r=.42, P=.02) was observed. We report one of the first studies to use digital wearable device-determined step count as an outcome variable in a placebo-controlled crossover trial of late sodium channel inhibition in participants with CMD. Our substudy demonstrates that late sodium channel inhibition was associated with a decreased step count overall, although the subgroup with angina improvement had a step count increase. Our findings suggest digital wearable device technology may provide new insights in clinical trial research. Clinicaltrials.gov NCT01342029; https://clinicaltrials.gov/ct2/show/NCT01342029 (Archived by WebCite at http://www.webcitation.org/6uyd6B2PO).
- Open Access
- 16 May 2017
- Published by JMIR Publications Inc. in JMIR Preprints
Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial (Preprint)
BACKGROUND Digital wearable devices provide a “real-world” assessment of physical activity and quantify intervention-related changes in clinical trials. However, the value of digital wearable device-recorded physical activity as a clinical trial outcome is unknown. OBJECTIVE Because late sodium channel inhibition (ranolazine) improves stress laboratory exercise duration among angina patients, we proposed that this benefit could be quantified and translated during daily life by measuring digital wearable device-determined step count in a clinical trial. METHODS We conducted a substudy in a randomized, double-blinded, placebo-controlled, crossover trial of participants with angina and coronary microvascular dysfunction (CMD) with no obstructive coronary artery disease to evaluate the value of digital wearable device monitoring. Ranolazine or placebo were administered (500-1000 mg twice a day) for 2 weeks with a subsequent 2-week washout followed by crossover to ranolazine or placebo (500-1000 mg twice a day) for an additional 2 weeks. The outcome of interest was within-subject difference in Fitbit Flex daily step count during week 2 of ranolazine versus placebo during each treatment period. Secondary outcomes included within-subject differences in angina, quality of life, myocardial perfusion reserve, and diastolic function. RESULTS A total of 43 participants were enrolled in the substudy and 30 successfully completed the substudy for analysis. Overall, late sodium channel inhibition reduced within-subject daily step count versus placebo (mean 5757 [SD 3076] vs mean 6593 [SD 339], P=.01) but did not improve angina (Seattle Angina Questionnaire-7 [SAQ-7]) (P=.83). Among the subgroup with improved angina (SAQ-7), a direct correlation with increased step count (r=.42, P=.02) was observed. CONCLUSIONS We report one of the first studies to use digital wearable device-determined step count as an outcome variable in a placebo-controlled crossover trial of late sodium channel inhibition in participants with CMD. Our substudy demonstrates that late sodium channel inhibition was associated with a decreased step count overall, although the subgroup with angina improvement had a step count increase. Our findings suggest digital wearable device technology may provide new insights in clinical trial research. CLINICALTRIAL Clinicaltrials.gov NCT01342029; https://clinicaltrials.gov/ct2/show/NCT01342029 (Archived by WebCite at http://www.webcitation.org/6uyd6B2PO)
- 16 May 2017
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessDaily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial (Preprint)
BACKGROUND Digital wearable devices provide a “real-world” assessment of physical activity and quantify intervention-related changes in clinical trials. However, the value of digital wearable device-recorded physical activity as a clinical trial outcome is unknown. OBJECTIVE Because late sodium channel inhibition (ranolazine) improves stress laboratory exercise duration among angina patients, we proposed that this benefit could be quantified and translated during daily life by measuring digital wearable device-determined step count in a clinical trial. METHODS We conducted a substudy in a randomized, double-blinded, placebo-controlled, crossover trial of participants with angina and coronary microvascular dysfunction (CMD) with no obstructive coronary artery disease to evaluate the value of digital wearable device monitoring. Ranolazine or placebo were administered (500-1000 mg twice a day) for 2 weeks with a subsequent 2-week washout followed by crossover to ranolazine or placebo (500-1000 mg twice a day) for an additional 2 weeks. The outcome of interest was within-subject difference in Fitbit Flex daily step count during week 2 of ranolazine versus placebo during each treatment period. Secondary outcomes included within-subject differences in angina, quality of life, myocardial perfusion reserve, and diastolic function. RESULTS A total of 43 participants were enrolled in the substudy and 30 successfully completed the substudy for analysis. Overall, late sodium channel inhibition reduced within-subject daily step count versus placebo (mean 5757 [SD 3076] vs mean 6593 [SD 339], P=.01) but did not improve angina (Seattle Angina Questionnaire-7 [SAQ-7]) (P=.83). Among the subgroup with improved angina (SAQ-7), a direct correlation with increased step count (r=.42, P=.02) was observed. CONCLUSIONS We report one of the first studies to use digital wearable device-determined step count as an outcome variable in a placebo-controlled crossover trial of late sodium channel inhibition in participants with CMD. Our substudy demonstrates that late sodium channel inhibition was associated with a decreased step count overall, although the subgroup with angina improvement had a step count increase. Our findings suggest digital wearable device technology may provide new insights in clinical trial research. CLINICALTRIAL Clinicaltrials.gov NCT01342029; https://clinicaltrials.gov/ct2/show/NCT01342029 (Archived by WebCite at http://www.webcitation.org/6uyd6B2PO)
- Open Access
- 12 September 2013
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 72 (1) , 124-136
Towards elimination of the dark-rim artifact in first-pass myocardial perfusion MRI: Removing Gibbs ringing effects using optimized radial imaging
Purpose Subendocardial dark‐rim artifacts (DRAs) remain a major concern in first‐pass perfusion (FPP) myocardial MRI and may lower the diagnostic accuracy for detection of ischemia. A major source of DRAs is the “Gibbs ringing” effect. We propose an optimized radial acquisition strategy aimed at eliminating ringing‐induced DRAs in FPP. Theory and Methods By studying the underlying point spread function (PSF), we show that optimized radial sampling with a simple reconstruction method can eliminate the oscillations in the PSF that cause ringing artifacts. We conducted realistic MRI phantom experiments and in vivo studies (n = 12 healthy humans) to evaluate the artifact behavior of the proposed imaging scheme in comparison to a conventional Cartesian imaging protocol. Results Simulations and phantom experiments verified our theoretical expectations. The in vivo studies showed that optimized radial imaging is capable of significantly reducing DRAs in the early myocardial enhancement phase (during which the ringing effect is most prominent and may obscure perfusion defects) while providing similar resolution and image quality compared with conventional Cartesian imaging. Conclusion The developed technical framework and results demonstrate that, in comparison to conventional Cartesian techniques, optimized radial imaging with the proposed optimizations significantly reduces the prevalence and spatial extent of DRAs in FPP imaging. Magn Reson Med 72:124–136, 2014.
- 12 September 2013
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 72 (1) , 124-136
Open AccessTowards elimination of the dark-rim artifact in first-pass myocardial perfusion MRI: Removing Gibbs ringing effects using optimized radial imaging
Purpose Subendocardial dark‐rim artifacts (DRAs) remain a major concern in first‐pass perfusion (FPP) myocardial MRI and may lower the diagnostic accuracy for detection of ischemia. A major source of DRAs is the “Gibbs ringing” effect. We propose an optimized radial acquisition strategy aimed at eliminating ringing‐induced DRAs in FPP. Theory and Methods By studying the underlying point spread function (PSF), we show that optimized radial sampling with a simple reconstruction method can eliminate the oscillations in the PSF that cause ringing artifacts. We conducted realistic MRI phantom experiments and in vivo studies (n = 12 healthy humans) to evaluate the artifact behavior of the proposed imaging scheme in comparison to a conventional Cartesian imaging protocol. Results Simulations and phantom experiments verified our theoretical expectations. The in vivo studies showed that optimized radial imaging is capable of significantly reducing DRAs in the early myocardial enhancement phase (during which the ringing effect is most prominent and may obscure perfusion defects) while providing similar resolution and image quality compared with conventional Cartesian imaging. Conclusion The developed technical framework and results demonstrate that, in comparison to conventional Cartesian techniques, optimized radial imaging with the proposed optimizations significantly reduces the prevalence and spatial extent of DRAs in FPP imaging. Magn Reson Med 72:124–136, 2014.
- 1 November 2009
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 3 (6) , 394-400
Coronary artery calcium scoring using a reduced tube voltage and radiation dose protocol with dual-source computed tomography
- 1 November 2009
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 3 (6) , 394-400
Coronary artery calcium scoring using a reduced tube voltage and radiation dose protocol with dual-source computed tomography